QCM
RXRX icon

QRG Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

QRG Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,306
Closed -$47K – 1239
2026
Q1 		$47K Buy
+15,306
New +$59.1K ﹤0.01% 1133
2025
Q3 		– Sell
-19,366
Closed -$98K – 1151
2025
Q2 		$98K Sell
19,366
-9,149
-32% -$44.9K ﹤0.01% 1104
2025
Q1 		$151K Buy
28,515
+2,244
+9% +$16.4K ﹤0.01% 1051
2024
Q4 		$178K Buy
26,271
+8,008
+44% +$53.8K ﹤0.01% 1048
2024
Q3 		$120K Buy
+18,263
New +$131K ﹤0.01% 1068
2023
Q4 		– Sell
-11,295
Closed -$86.4K – 1063
2023
Q3 		$86.4K Buy
+11,295
New +$113K ﹤0.01% 967

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

QRG Capital Management's RXRX Position: Q2 2026 in Review

QRG Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2026, closing a stake of 15,306 shares — an estimated $47K sold.

QRG Capital Management first reported a position in RXRX in Q3 2023 and held it in 6 quarters. The position peaked at $178K in Q4 2024. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • QRG Capital Management reported no remaining Recursion Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • QRG Capital Management sold 15,306 Recursion Pharmaceuticals shares in Q2 2026, an estimated $47K.
  • QRG Capital Management first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 6 quarters.
  • QRG Capital Management's Recursion Pharmaceuticals position peaked at $178K in Q4 2024.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.